• About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • Documents
  • news
    • news
    • Press releases
    • Blog
    • Press Coverage
    • Events
  • Login
  • Contact

o2h-ventures

  • About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • Documents
  • news
    • news
    • Press releases
    • Blog
    • Press Coverage
    • Events
  • Login
  • Contact

Don’t invest unless you’re prepared to lose all your money invested. This is a high risk investment. You could lose all the money you invest and are unlikely to be protected if something goes wrong. Take 2 mins to learn more

May 2022, o2h Ventures Fund Newsletter, SEIS fund close deadline June 30th 2022
May 28 2022

We hope that you are looking forward to a warm summer!

We had a good closing of both the funds last month which also marked the end of tax year 2021-2022. o2h Ventures have stayed focused on building a strong pipeline of exciting early-stage biotech companies. We see strong deal flow at the Seed stage and the slight cooling of the markets has taken off some of the froth from the valuations which is not necessarily a bad thing when on the investing side!.

Several of our portfolios are closing Series A funding as the companies have now had a few years to cook, and on the whole, they seem to be on track. We expect new clinical data from both Small Pharma (TSX) and Exonate (Janssen) next month, so hopefully will be a positively busy time for us.

Whilst the markets are turbulent we keep our focus on big pharma as collaborative/exit partners. Not only did many of the large pharmaceutical companies have a boost to earnings due to ‘covid’ they have a defensive investment thesis.

Recent Investments:

Alevin Therapeutics – Alevin Therapeutics Ltd was founded in March 2022 with the aim of developing safe and effective medicines for patients with life-threatening diseases. Alevin Therapeutics is a spin-out from the University of Nottingham and is developing a platform of novel small molecule RGD integrin inhibitors with superior drug-like qualities.

Oxford Drug Design – Oxford Drug Design Limited, a biotech company with a proprietary computational and machine learning platform, has raised £2.2m in funding from existing investors ACF Investors, o2h Ventures, Meltwind Advisory, a number of returning angels and new investors and the US-based R42 Group.

Monument Therapeutics – Monument Therapeutics, Monument Tx is an independent UK based biotechnology company formed in 2019 as a spin-out from Cambridge Cognition. Monument Tx develops products to treat serious diseases of the central nervous system.

Deals Closing Soon:

Neurocentrx – o2h Ventures is pleased to announce an EIS investment into Neurocentrx Pharma Ltd, a psychedelic focused biotech company based in Edinburgh developing orally delivered drug product formulations of ketamine that are primarily aimed to treat mood disorders like Depression.

Spirea – Spirea Limited, a biotechnology company created to deliver the next generation of antibody drug conjugate (ADC) cancer therapeutics, has today announced that it has secured funding of £2.4 million.

Qkine – Based in the Cambridge Science Park, Qkine combines proprietary protein production processes developed at the University of Cambridge with protein engineering techniques to develop unique products that tackle fundamental biological and scale-up challenges.

Portfolio News:

  • Arecor Therapeutics plc Presents Full Data from Positive Phase I Clinical Trial of AT278 Ultra-Concentrated Ultra-Rapid Acting Insulin for Diabetes At ATTD Meeting. Read more.
  • PhoreMost expands into new facility at Unity Campus in Cambridge and promotes Dr Neil Torbett to Chief Executive Officer. Read more.
  • Monument Therapeutics raises additional £0.5 million to take anti-neuroinflammation candidate MT1980 into clinic. Read more.
  • Oppilotech and Evariste Technologies Announce Partnership to Develop First-in-Class Antibacterial Programme. Read more.
  • Small Pharma hosted an evening salon event in London, bringing together a diverse group to connect and engage in important conversations about the future of psychedelic therapy for mentalhealth. See here.

Events:

Sunil Shah, CEO of o2h Ventures featured in the Biotech-focused investment event hosted by The Chicago Booth Angels Network of London.

Sunil Shah CEO o2h Ventures

SEIS Deals in Pipeline:

CardiaTec– Cardiovascular

An AI drug discovery company specialized in cardiovascular disease (CVD), first focusing on coronary artery disease (CAD).

Cardiff Spin-out – Neurosciences

Early discussions regarding a formulation platform Start-Up opportunity from Cardiff University.

Five Alaram Bio – Longevity

Seeking to provide part of a match award to a £300K UK Innovate award around wound healing.

Opal Therapeutics – Psychedelic

The company is developing two programmes in the area of neuro-psychiatric space / psychedelic space. Seeking to target known psychedelic target with novel chemistry.

SEIS Fund Closing:

The fund has a closing date of 31 June 2022 and is targeting significant or full deployment by the end of the tax year. We will develop a portfolio of at least 3 companies. The o2h human health SEIS fund has a minimum Subscription of £10,000, which will be invested into seed stage SEIS qualifying companies covering novel drug discovery along with enabling services, tools and AI technologies that can impact human health.

Investing and onboarding into the o2h Ventures funds is straight-forward via the o2h Ventures App and typically takes 5-10mins. If you would like to know more about the fund, please visit – o2h human health SEIS fund or we can also arrange a call and provide further information, just send a short note to invest@o2h.com and we will schedule a call accordingly.

Disclaimer:
Please refer to the relevant fund’s full risk warnings contained in their Information Memorandums.
Your capital is at risk. Investing in early-stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. o2h Ventures’ funds are targeted exclusively at sophisticated or high net worth investors who understand these risks and make their own investment decisions. *Tax relief depends on an individual’s circumstances and may change in the future. In addition, the availability of tax relief depends on the company invested in maintaining its qualifying status. Past performance is not a reliable indicator of future performance. You should not rely on any past performance as a guarantee of future investment performance.

o2h Ventures Ltd is a limited company registered in England and Wales under number 11397838 and is authorised and regulated by the Financial Conduct Authority (FRN 812245). The registered office and principal place of business is Hauxton House, Mill Scitech Park, Mill Lane, Hauxton, Cambridge, CB22 5HX, United Kingdom. Further details about o2h can be found on our website at https://o2hventures.com.

Connect with us
  • linkedin
  • twitter
  • instagram
  • facebook
  • youtube
o2h-ventures
related stories
  • Oct 2022, o2h Ventures Fund Newsletter, KI EIS Closing, EISA events 1 November, 2022
  • Aug-Sept 2022, o2h Ventures Fund Newsletter, fifty percent of our companies led by female and more portfolio updates 30 September, 2022
  • July 2022, o2h Ventures Fund Newsletter, Deals executed in Alevin Therapeutics, Neurofenix, Five Alarm Bio 1 August, 2022
o2h-ventures
The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years.
Useful Links
  • About Us
  • Blog
  • Documents Centre
  • Contact Us
  • Team
News
  • Oct 2022, o2h Ventures Fund Newsletter, KI EIS Closing, EISA events
  • Aug-Sept 2022, o2h Ventures Fund Newsletter, fifty percent of our companies led by female and more portfolio updates
  • July 2022, o2h Ventures Fund Newsletter, Deals executed in Alevin Therapeutics, Neurofenix, Five Alarm Bio
Connect with us
  • linkedin
  • twitter
  • instagram
  • facebook
© 2023 o2h ventures
  • Privacy Policy
  • Blog
  • Contact us
o2h ventures Limited is regulated and authorised by the Financial Conduct Authority (FRN 812245). Capital at risk, only suitable for high net worth and sophisticated investors

Risk Information

Due to the potential for losses, the Financial Conduct Authority (FCA) considers this investment to be high risk

What are the key risks?

1 – You could lose all the money you invest

• If the business you invest in fails, you are likely to lose 100% of the money you invest. Most start-up businesses fail.

2 – You are unlikely to be protected if something goes wrong

• Protection from the Financial Services Compensation Scheme (FSCS), in relation to claims against failed regulated firms, does not cover poor investment performance. Try the FSCS investment protection checker here. (https://www.fscs.org.uk/check/investment-protection-checker)

• Protection from the Financial Ombudsman Service (FOS) does not cover poor investment performance. If you have a complaint against an FCA-regulated firm, FOS may be able to consider it. Learn more about FOS protection here. (https://www.financial-ombudsman.org.uk/consumers)

3 – You won’t get your money back quickly

• Even if the business you invest in is successful, it may take several years to get your money back. You are unlikely to be able to sell your investment early.

• The most likely way to get your money back is if the business is bought by another business or lists its shares on an exchange such as the London Stock Exchange. These events are not common.

• If you are investing in a start-up business, you should not expect to get your money back through dividends. Start-up businesses rarely pay these.

4 – Don’t put all your eggs in one basket

• Putting all your money into a single business or type of investment for example, is risky. Spreading your money across different investments makes you less dependent on any one to do well.

• A good rule of thumb is not to invest more than 10% of your money in high-risk investments (https://www.fca.org.uk/investsmart/5-questions-ask-you-invest)

5 – The value of your investment can be reduced

• The percentage of the business that you own will decrease if the business issues more shares. This could mean that the value of your investment reduces, depending on how much the business grows. Most start-up businesses issue multiple rounds of shares.

• These new shares could have addition rights that your shares don’t have, such as the right to receive a fixed dividend, which could further reduce your chances of getting a return on your investment.

If you are interested in learning more about how to protect yourself, visit the FCA’s website here (https://www.fca.org.uk/investsmart)